Aprea Therapeutics Inc Cash Flow Conversion Efficiency
Aprea Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Aprea Therapeutics Inc (APRE) has a cash flow conversion efficiency ratio of -0.085x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.28 Million) by net assets ($38.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aprea Therapeutics Inc (2007–2025)
Cash flow conversion efficiency of Aprea Therapeutics Inc from 2007 to 2025. This chart illustrates how Aprea Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Aprea Therapeutics Inc share price for real-time trading data and today's change.
Aprea Therapeutics Inc Cash Flow Conversion Ratio Explained
Aprea Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aprea Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aprea Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Aprea Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EXPLOITS DISCOVERY CORP.
F:634
|
-0.041x |
|
Saxlund Group AB
ST:SAXG
|
-0.028x |
|
Xylo Technologies Ltd.
NASDAQ:XYLO
|
-0.007x |
|
Foresight Group Holdings Limited
LSE:FSG
|
0.305x |
|
Hwa Tai Industries Bhd
KLSE:8478
|
-0.010x |
|
Innelec Multimedia
PA:ALINN
|
-0.574x |
|
Ambipar Emergency Response
NYSE MKT:AMBI
|
0.074x |
|
In-Touch Survey Systems Ltd.
V:INX
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Aprea Therapeutics Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Aprea Therapeutics Inc from 2007 to 2025. Review APRE free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $12.44 Million | $-12.89 Million | -1.036x | -47.60% |
| 2024-12-31 | $19.31 Million | $-13.56 Million | -0.702x | -5.31% |
| 2023-12-31 | $18.26 Million | $-12.18 Million | -0.667x | +31.64% |
| 2022-12-31 | $25.64 Million | $-25.01 Million | -0.975x | -28.13% |
| 2021-12-31 | $49.51 Million | $-37.69 Million | -0.761x | -40.94% |
| 2020-12-31 | $77.40 Million | $-41.80 Million | -0.540x | -151.25% |
| 2019-12-31 | $124.24 Million | $-26.71 Million | -0.215x | -172.51% |
| 2018-12-31 | $-51.44 Million | $-15.25 Million | 0.296x | -24.27% |
| 2017-12-31 | $-35.77 Million | $-14.00 Million | 0.392x | -56.40% |
| 2007-12-31 | $-2.11 Million | $-1.90 Million | 0.898x | -- |
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tum… Read more